- Another Unmet Need against Residual Risk of Atherosclerotic Cardiovascular Disease: Can “Thrombin Pathway” Be a New Target for Therapy?
-
Kim HK, Tantry US, Gurbel PA, Jeong YH
- KMID: 2505737
- Korean Circ J.
- 2020 Sep;50(9):817-821.
- doi: 10.4070/kcj.2020.0287
-
- CITED
-
- Close
- SHARE
-
- Close
- Temporal Variability of Platelet Reactivity Phenotype: Another Barrier to Personalized Antiplatelet Strategy Guided by Platelet Function Testing
-
Jeong YH, Tantry US, Gurbel PA
- KMID: 2460532
- Korean Circ J.
- 2019 Nov;49(11):1062-1065.
- doi: 10.4070/kcj.2019.0260
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Current Antiplatelet Treatment Strategy in Patients with Diabetes Mellitus
-
Jung JH, Tantry US, Gurbel PA, Jeong YH
- KMID: 1805892
- Diabetes Metab J.
- 2015 Apr;39(2):95-113.
- doi: 10.4093/dmj.2015.39.2.95
Patients with diabetes mellitus (DM) have accelerated atherosclerosis with an increased risk for atherothrombotic cardiovascular complications. A state of high platelet reactivity and activation, hypercoagulability (prothrombotic state) and a subdued... -
- CITED
-
- Close
- SHARE
-
- Close
- Ethnic Difference of Thrombogenicity in Patients with Cardiovascular Disease: a Pandora Box to Explain Prognostic Differences
-
Kim HK, Tantry US, Park HW, Shin ES, Geisler T, Gorog DA, Gurbel PA, Jeong YH
- KMID: 2513518
- Korean Circ J.
- 2021 Mar;51(3):202-221.
- doi: 10.4070/kcj.2020.0537
Arterial and venous atherothrombotic events are finely regulated processes involving a complex interplay between vulnerable blood, vulnerable vessel, and blood stasis. Vulnerable blood (‘thrombogenicity’) comprises complex interactions between cellular components... -
- CITED
-
- Close
- SHARE
-
- Close
